NCT00401180View on ClinicalTrials.gov

Docetaxel and Temozolomide in Treating Patients With Metastatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

docetaxel

administered weekly in 5 escalating doses of 25 to 35 mg/ m(2) as a one-hour bolus intravenous infusion for 3 consecutive weeks.

DRUG

temozolomide

administered orally daily for 3 weeks (escalating doses of 75 to 100 mg/m(2)). Cycles were repeated at 4 week intervals.

Trial Locations (1)

44106-5065

Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

The Cleveland Clinic

OTHER

NCT00401180 - Docetaxel and Temozolomide in Treating Patients With Metastatic Cancer | Biotech Hunter | Biotech Hunter